Brii Biosciences Past Earnings Performance

Past criteria checks 0/6

Brii Biosciences has been growing earnings at an average annual rate of 41.3%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 15.3% per year.

Key information

41.3%

Earnings growth rate

60.6%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-15.3%
Return on equity-9.6%
Net Margin-691.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Brii Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:7SS Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2438-265205327
31 Mar 2447-220202365
31 Dec 2356-175198403
30 Sep 2395-251193394
30 Jun 23134-327189384
31 Mar 23128-405192412
31 Dec 22122-484195441
30 Sep 2299-1,021223518
30 Jun 2275-1,558251595
31 Mar 2284-2,861230545
31 Dec 2193-4,164208495
30 Sep 21100-3,999169631
30 Jun 21107-3,835130768
31 Mar 2194-2,512117822
31 Dec 2082-1,190103876
31 Dec 1920-5216384

Quality Earnings: 7SS is currently unprofitable.

Growing Profit Margin: 7SS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 7SS is unprofitable, but has reduced losses over the past 5 years at a rate of 41.3% per year.

Accelerating Growth: Unable to compare 7SS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 7SS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).


Return on Equity

High ROE: 7SS has a negative Return on Equity (-9.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies